$20 0.7 3.4%
Last Trade - 03/04/20
| Market Cap | ÂŁ466.7m |
| Enterprise Value | ÂŁ355.4m |
| Revenue | ÂŁn/a |
| Position in Universe | 2433rd / 6308 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Akero Therapeutics, Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing treatments for serious metabolic diseases. The Company is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.
| Last Annual | December 31st, 2019 |
| Last Interim | December 31st, 2019 |
| Incorporated | January 24, 2017 |
| Public Since | June 20, 2019 |
| No. of Shareholders: | 11 |
| No. of Employees: | 13 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 28,607,913 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 170 Harbor Way, SOUTH SAN FRANCISCO, 94080-6101, United States |
| Web | https://www.akerotx.com/ |
| Phone | +1 650 4876488 |
| Auditors | Deloitte & Touche LLP |
